Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma

Glioblastomas are characterized by amplification of EGFR. Approximately half of tumors with EGFR over-expression also express a constitutively active ligand independent EGFR variant III (EGFRvIII). While current treatments emphasize surgery followed by radiation and chemotherapy with Temozolomide (T...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Velpula, Kiran K., Guda, Maheedhara R., Sahu, Kamlesh, Tuszynski, Jack, Asuthkar, Swapna, Bach, Sarah E., Lathia, Justin D., Tsung, Andrew J.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482605/
https://ncbi.nlm.nih.gov/pubmed/28410193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16767
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars